ROCK1 and atherosclerosis: Additionally, we identified 4 new MMVD stage B2 targets (MDM2, ROCK1, RIPK1, and SNAP23) that have been studied in many cardiovascular diseases in human medicine, such as chronic heart failure, atherosclerosis, and diabetic cardiomyopathy.